Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

6.2%

5 terminated/withdrawn out of 81 trials

Success Rate

93.5%

+7.0% vs industry average

Late-Stage Pipeline

20%

16 trials in Phase 3/4

Results Transparency

38%

27 of 72 completed trials have results

Key Signals

3 recruiting27 with results

Enrollment Performance

Analytics

Phase 1
40(49.4%)
Phase 2
18(22.2%)
Phase 3
13(16.0%)
Early Phase 1
7(8.6%)
Phase 4
3(3.7%)
81Total
Phase 1(40)
Phase 2(18)
Phase 3(13)
Early Phase 1(7)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (81)

Showing 20 of 81 trials
NCT07144345Phase 3Recruiting

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp

Role: lead

NCT07546214Phase 1Completed

A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.

Role: lead

NCT07144852Phase 3Recruiting

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities

Role: lead

NCT07469228Phase 1Completed

A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris

Role: lead

NCT07133308Phase 3Recruiting

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

Role: lead

NCT05041803Phase 3Completed

European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Role: lead

NCT03898479Phase 2Active Not Recruiting

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Role: lead

NCT04321070Phase 1Completed

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

Role: lead

NCT06733402Phase 1Completed

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris

Role: lead

NCT06673654Phase 1Completed

A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.

Role: lead

NCT06673641Phase 1Completed

A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.

Role: lead

NCT03094403Phase 1Completed

To Evaluate the Therapeutic Equivalence and Safety of Azelaic Acid 15% Topical Gel

Role: lead

NCT02985736Phase 4Completed

Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray

Role: collaborator

NCT02983981Phase 4Completed

Topical Psoriasis Study for Patients Receiving Biologic Therapy

Role: collaborator

NCT06305637Phase 1Completed

A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.

Role: lead

NCT06063473Phase 1Completed

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris

Role: lead

NCT02340169Phase 4Completed

Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis

Role: lead

NCT03645499Phase 1Completed

An Open-Label Study to Assess Safety

Role: lead

NCT05282771Early Phase 1Completed

A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.

Role: lead

NCT05148689Phase 1Completed

A Study Comparing Oxymetazoline 1% Cream to RHOFADE

Role: lead